Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer

ErbB-3 and its ligand NRG-1β are key players in driving oncogenic signaling and resistance to therapy through the activation of the PI3K/Akt pathway. We have recently reported that EV20, a humanized anti-ErbB3 antibody, possesses a marked antitumor activity in a variety of human tumor models, includ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogenesis
Main Authors: Ghasemi, R, Rapposelli, I G, Capone, E, Rossi, C, Lattanzio, R, Piantelli, M, Sala, G, Iacobelli, S
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5189962/
https://ncbi.nlm.nih.gov/pubmed/25133484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/oncsis.2014.31
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados